Clinical Effect of Angong Niuhuang Pill in the Treatment of Cerebral Vasospasm after Craniocerebral Injury

Abstract

Abstract: Objective To study the therapeutic effect of Angong Niuhuang Pill on cerebral vasospasm in patients with craniocerebral injury. Methods A total of 72 patients with cerebral vasospasm admitted to Zhuji People's Hospital after craniocerebral injury from June 2019 to June 2021 were selected and divided into the control group and the treatment group, with 36 cases in each groups.The control group was treated with common treatment methods combined with basic treatment methods; the treatment group was additionally treated with Angong Niuhuang Pill on the basis of the treatment of the control group.The changes of Glass Score (GCS) before and after 14 days of treatment were compared between the two groups, and the blood flow velocity of the middle cerebral artery was measured by transcranial Doppler ultrasound and was compared between the two groups. Results The blood flow velocity of the middle cerebral artery in the treatment group was significantly lower than that in the control group at 3, 7, and 14 days after treatment, and the difference was statistically significant(P<0.05).The Glass score after treatment in the treatment group was significantly higher than that in the control group, and the difference was statistically significant(P<0.05). Conclusion Angong Niuhuang Pill has the effect of dilating blood vessels and inhibiting the inward flow of calcium ions in post-traumatic brain injury patients, thereby reducing cerebral edema, regulating cerebral blood flow, reducing the average flow rate of the middle cerebral artery, and therefore reducing the occurrence of traumatic cerebral vasospasm.

Key words: Angong Niuhuang Pill, nimodipine, traumatic cerebral vasospasm

CLC Number:

R651

XU Long-biao, HUANG Huan-ming, WU Tian-ya, ZHU Jia-ming, CHEN Shi-qi, WAN Ye-dong, WANG Guan-hua. Clinical Effect of Angong Niuhuang Pill in the Treatment of Cerebral Vasospasm after Craniocerebral Injury[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(15): 1-4.

References

[1] Perrein A, Petry L, Reis A, et al.Cerebral vasospasm after traumatic brain injury: an update[J].Minerva Anestesiol,2015,81(11):1219-1228.
[2] 周林裕,代永庆,杨志波,等.脑血疏联合尼莫地平对自发性蛛网膜下腔出血脑血管痉挛和迟发性脑缺血的影响[J].湖北中医药大学学报,2020,22(3):75-78.
[3] 朱晓宇,郭胜亚,徐懿乔,等.安宫牛黄丸防治脑血管疾病作用研究[J].药物评价研究,2017,40(8):1067-1072.
[4] 张真真,梁艳,崔瑛,等.清开灵注射液的临床应用及安全性研究进展[J].吉林中医药,2017,37(3):320-324.
[5] 王计伟,张建宁.颅脑损伤后脑血管痉挛的研究进展[J].中华神经外科杂志,2020,36(1):95-98.
[6] 李文娅. 醒脑静注射液联合尼莫地平治疗颅脑损伤后脑血管痉挛[J].2017,7(22):111-112.
[7] 应盈,徐象威,叶汝勇.参麦注射液联合尼莫地平治疗外伤性蛛网膜下腔出血伴脑血管痉挛的效果观察[J].浙江医学,2019,41(5):457-461.
[8] 朱传贤,霍贵玲,代怀静,等.尼莫地平预防蛛网膜下隙出血后脑血管痉挛疗效观察[J].临床医药实践,2006,15(3):191-192.
[9] 赵丽,王茜.安宫牛黄丸治疗颅脑外伤昏迷临床研究[J].实用中医药杂志,2015,31(11):995-996.
[10] 郜风清. 颅脑创伤后脑血管痉挛发生的影响因素[J].中国实用神经疾病杂志,2015,18(1):42-43.
[11] Sachin A B, Sumit S, Deepak A, et al.Severe head injury in the elderly: risk factor assessment and outcome analysis in a series of 100 consecutive patients at a Level 1 trauma centre[J].Indian Journal of Neurotrauma,2011,8(2):77-82.
[12] Gritti P, Zangari R, Carobbio A, et al.Acute and Subacute Outcome Predictors in Moderate and Severe Traumatic Brain Injury: A Retrospective Monocentric Study[J].World Neurosurg,2019,128:e531-e540.
[13] Al-Mufti F, Amuluru K, Changa A, et al.Traumatic brain injury and intracranial hemorrhage-induced cerebral vasospasm: a systematic review[J]. Neurosurg Focus,2017,43(5):E14.
[14] 陈晨,霍国进,白磊.创伤性颅内出血后脑血管痉挛的影响因素分析[J].卒中与神经疾病,2019,26(3):303-306.
[15] Kramer D R, Winer J L, Pease B A, et al.Cerebral vasospasm in traumatic brain injury[J].Neurol Res Int,2013,2013:415813.
[16] Alford P W, Dabiri B E, Goss J A, et al.Blast-induced phenotypic switching in cerebral vasospasm[J].Proc Natl Acad Sci U S A. 2011, 108(31):12705-12710.
[17] 王计伟. 脑源性微粒在颅脑创伤后血管痉挛中的作用研究[D].天津:天津医科大学,2018.
[18] 谢嵩泉,赵龙,彭姝婷,等.法舒地尔联合尼莫地平治疗脑动脉瘤性脑血管痉挛疗效及安全性的Meta分析[J].实用医学杂志,2021,37(7): 924-930.
[19] Tagami T, Kuwamoto K, Watanabe A, et al.Effect of Triple-H Prophylaxis on Global End-Diastolic Volume and Clinical Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage[J].Neurocritical Care,2014, 21(3):462-469.
[20] 高肖宾. 四种常用的“牛黄药”[J].中华养生保健,2003(8):40.
[21] 姚卫海. 中医教你正确使用“急救三宝”[J].中华养生保健(上半月),2008(7):10-11.
[22] 崔爱瑛. 安宫牛黄丸的药理及临床研究进展[J].中国实验方剂学杂志,2012,18(20):341-344.
[23] Zhao P C, Huang Z S, Xu S N, et al.Adjuvant treatment with Angong Niuhuang pills in treating traumatic brain damage:a meta-analysis of randomized controlled trials[J]. Annals of palliative medicine,2020,10(2):1569-1577.
[24] Macdonald R L, Higashida R T, Keller E, et al.Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomized, double blind, placebo-controlled phase 3 trial (CONSCIOUS-2)[J].Lancet Neurology,2011, 10(7):618-625.